Local impact of the English arm of the UK Bowel Cancer Screening Pilot Study

被引:21
作者
Goodyear, S. J. [1 ,4 ]
Stallard, N. [2 ]
Gaunt, A.
Parker, R. [3 ]
Williams, N.
Wong, L.
机构
[1] Coventry & Warwickshire NHS Trust, Clin Sci Res Inst, Univ Hosp, Dept Surg, Coventry CV2 2DX, W Midlands, England
[2] Univ Warwick, Dept Med Stat, Warwick Med Sch, Coventry CV2 2DX, W Midlands, England
[3] Rugby UHCW NHS Trust, Hosp St Cross, Coventry CV4 7AL, W Midlands, England
[4] Univ Warwick, Clin Sci Res Inst, Coventry, W Midlands, England
关键词
D O I
10.1002/bjs.6230
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The English arm of the UK Bowel Cancer Screening Pilot study recently concluded its third round. The primary aim was to assess the impact of faecal occult blood test (FOBT) screening on the detection of symptomatic (non-screen-detected) cancers within the target age group (50-69 years). The secondary aim was to assess differences between screened and non-screened cohorts in Dukes' classification at diagnosis. Methods: This population-based study utilized retrospective analysis of existing validated colorectal cancer (CRC) data over 5 years (April 2000 to March 2005), encompassing rounds one and two of screening. Results: There was a 23 per cent (P = 0.011) reduction in the diagnosis of over the 5 years. Presentations with symptomatic cancer reduced by 49 per cent (P = 0.049), with a proportionate (2.6-fold) rise in the detection of screened (asymptomatic) malignancy. Cancers were diagnosed at an earlier stage in the screened population, with significantly more Dukes' A tumours than in the non-screen-detected cohort (P < 0.001) and an estimated odds ratio of 0.27 (95 per cent confidence interval 0.08 to 0.91) (P = 0.035) for Dukes' 'D' cancers. Conclusion: FOBT screening resulted in a significant reduction in the number of symptomatic cancers detected within the target age group. Tumours detected by screening were diagnosed at an earlier pathological stage.
引用
收藏
页码:1172 / 1179
页数:8
相关论文
共 39 条
[1]   Fecal occult blood testing for colorectal cancer - Can we afford to do this? [J].
Ahlquist, DA .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1997, 26 (01) :41-&
[2]  
*AM JOINT COMM CAN, 1998, AJCC CANC STAG MAN
[3]  
[Anonymous], ENGLISH PILOT BOWEL
[4]   The place of fecal occult blood test in colorectal cancer screening in 2006: The US perspective [J].
Bond, JH .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (02) :219-221
[5]  
BOND JH, 2006, US ONCOLOGICAL D JUN, P1
[6]  
Bond John H, 2002, Gastrointest Endosc Clin N Am, V12, P11, DOI 10.1016/S1052-5157(03)00054-0
[7]   Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review [J].
Burch, J. A. ;
Soares-Weiser, K. ;
St John, D. J. B. ;
Duffy, S. ;
Smith, S. ;
Kleijnen, J. ;
Westwood, M. .
JOURNAL OF MEDICAL SCREENING, 2007, 14 (03) :132-137
[8]  
*CANC RES UK, GOV LAUNCH CANC REF
[9]   The role of GPs in increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy) [J].
Federici, A ;
Rossi, PG ;
Bartolozzi, F ;
Farchi, S ;
Borgia, P ;
Guastcchi, G .
CANCER CAUSES & CONTROL, 2006, 17 (01) :45-52
[10]   Cutting cost and increasing access to colorectal cancer screening: Another approach to following the guidelines [J].
Fisher, JA ;
Fikry, C ;
Troxel, AB .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (01) :108-113